Epha2 is a critical oncogene in melanoma

Oncogene

Volumn 30, Issue 50, 2011, Pages 4921-4929

  Udayakumar, D ^a   Zhang, G ^b   Ji, Z ^a   Njauw, C N ^a   Mroz, P ^a   Tsao, H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

EphA2; melanoma; survival

Indexed keywords

B RAF KINASE; EPHRIN RECEPTOR A2; PROTEIN P53; SHORT HAIRPIN RNA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOGENICITY; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MIGRATION INHIBITION; MOUSE; NONHUMAN; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ULTRAVIOLET RADIATION;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MELANOMA; ONCOGENE PROTEINS; RECEPTOR, EPHA2; ULTRAVIOLET RAYS; UP-REGULATION;

EID: 83555166269     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.210     Document Type: Article

References (41)

1. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM et al. (1987). A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47: 3239-3245. (Pubitemid 17082655)
2. Andres AC, Reid HH, Zurcher G, Blaschke RJ, Albrecht D, Ziemiecki A. (1994). Expression of two novel eph-related receptor protein tyrosine kinases in mammary gland development and carcinogen-esis. Oncogene 9: 1461-1467. (Pubitemid 24123665)
3. Bogan C, Chen J, O'Sullivan MG, Cormier RT. (2009). Loss of EphA2 receptor tyrosine kinase reduces ApcMin/+ tumorigenesis. Int J Cancer 124: 1366-1371.
4. Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C et al. (2010). CD95 promotes tumour growth. Nature 465: 492-496.
5. Connor RJ, Menzel P, Pasquale EB. (1998). Expression and tyrosine phosphorylation of Eph receptors suggest multiple mechanisms in patterning of the visual system. Dev Biol 193: 21-35. (Pubitemid 28096578)
6. Cui XD, Lee MJ, Yu GR, Kim IH, Yu HC, Song EY et al. (2010). EFNA1 ligand and its receptor EphA2: potential biomarkers for hepatocellular carcinoma. Int J Cancer 126: 940-949.
7. Debnath J, Muthuswamy SK, Brugge JS. (2003). Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30: 256-268. (Pubitemid 36677560)
8. Dohn M, Jiang J, Chen X. (2001). Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis. Oncogene 20: 6503-6515. (Pubitemid 32980275)
9. Easty DJ, Hill SP, Hsu MY, Fallowfield ME, Florenes VA, Herlyn M et al. (1999). Up-regulation of ephrin-A1 during melanoma progression. Int J Cancer 84: 494-501.
10. Ganju P, Shigemoto K, Brennan J, Entwistle A, Reith AD. (1994). The Eck receptor tyrosine kinase is implicated in pattern formation during gastrulation, hindbrain segmentation and limb development. Oncogene 9: 1613-1624. (Pubitemid 24163387)
11. Han L, Dong Z, Qiao Y, Kristensen GB, Holm R, Nesland JM et al. (2005). The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas. Gynecol Oncol 99: 278-286. (Pubitemid 41502831)
12. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. (2003). Molecular plasticity of human melanoma cells. Oncogene 22: 3070-3075. (Pubitemid 36713757)
13. Herath NI, Spanevello MD, Sabesan S, Newton T, Cummings M, Duffy S et al. (2006). Over-expression of Eph and ephrin genes in advanced ovarian cancer: ephrin gene expression correlates with shortened survival. BMC Cancer 6: 144.
14. Hess AR, Seftor EA, Gruman LM, Kinch MS, Seftor RE, Hendrix MJ. (2006). VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculo-genic mimicry. Cancer Biol Ther 5: 228-233. (Pubitemid 43327544)
15. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. (2003). Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 63: 5198-5202. (Pubitemid 37139827)
16. Kamat AA, Coffey D, Merritt WM, Nugent E, Urbauer D, Lin YG et al. (2009). EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer 115: 2684-2692.
17. Kataoka H, Igarashi H, Kanamori M, Ihara M, Wang JD, Wang YJ et al. (2004). Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer. Cancer Sci 95: 136-141. (Pubitemid 38404314)
18. Liang CC, Park AY, Guan JL. (2007). In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2: 329-333. (Pubitemid 47040047)
19. Liu Y, Zhang X, Qiu Y, Huang D, Zhang S, Xie L et al. (2010). Clinical significance of EphA2 expression in squamous-cell carcinoma of the head and neck. J Cancer Res Clin Oncol 137: 761-769.
20. Lu C, Shahzad MM, Wang H, Landen CN, Kim SW, Allen J et al. (2008). EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther 7: 1098-1103.
21. Margaryan NV, Strizzi L, Abbott DE, Seftor EA, Rao MS, Hendrix MJ et al. (2009). EphA2 as a promoter of melanoma tumorigenicity. Cancer Biol Ther 8: 279-288.
22. Menges CW, McCance DJ. (2008). Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptor. Oncogene 27: 2934-2940. (Pubitemid 351620455)
23. Miao H, Li DQ, Mukherjee A, Guo H, Petty A, Cutter J et al. (2009). EphA2 mediates ligand-dependent inhibition and ligand-indepen-dent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell 16: 9-20.
24. Miyazaki T, Kato H, Fukuchi M, Nakajima M, Kuwano H. (2003). EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int J Cancer 103: 657-663. (Pubitemid 36091471)
25. Moore-Scott BA, Opoka R, Lin SC, Kordich JJ, Wells JM. (2007). Identification of molecular markers that are expressed in discrete anterior-posterior domains of the endoderm from the gastrula stage to mid-gestation. Dev Dyn 236: 1997-2003. (Pubitemid 47076028)
26. Nemoto T, Ohashi K, Akashi T, Johnson JD, Hirokawa K. (1997). Overexpression of protein tyrosine kinases in human esophageal cancer. Pathobiology 65: 195-203. (Pubitemid 27472525)
27. Parri M, Taddei ML, Bianchini F, Calorini L, Chiarugi P. (2009). EphA2 reexpression prompts invasion of melanoma cells shifting from mesenchymal to amoeboid-like motility style. Cancer Res 69: 2072-2081.
28. Ruiz JC, Robertson EJ. (1994). The expression of the receptor-protein tyrosine kinase gene, eck, is highly restricted during early mouse development. Mech Dev 46: 87-100. (Pubitemid 24179066)
29. Seftor EA, Meltzer PS, Schatteman GC, Gruman LM, Hess AR, Kirschmann DA et al. (2002). Expression of multiple molecular phenotypes by aggressive melanoma tumor cells: role in vasculo-genic mimicry. Crit Rev Oncol Hematol 44: 17-27. (Pubitemid 35175468)
30. Straume O, Akslen LA. (2002). Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression. Am J Pathol 160: 1009-1019. (Pubitemid 34224589)
31. Sulman EP, Tang XX, Allen C, Biegel JA, Pleasure DE, Brodeur GM et al. (1997). ECK, a human EPH-related gene, maps to 1p36.1, a common region of alteration in human cancers. Genomics 40: 371-374. (Pubitemid 27124104)
32. Taddei ML, Parri M, Angelucci A, Onnis B, Bianchini F, Giannoni E et al. (2009). Kinase-dependent and-independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis. Am J Pathol 174: 1492-1503.
33. Tsao H, Goel V, Wu H, Yang G, Haluska FG. (2004). Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 122: 337-341. (Pubitemid 38281053)
34. Vaught D, Chen J, Brantley-Sieders DM. (2009). Regulation of mammary gland branching morphogenesis by EphA2 receptor tyrosine kinase. Mol Biol Cell 20: 2572-2581.
35. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR. (2008). Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 132: 363-374. (Pubitemid 351191995)
36. Walker-Daniels J, Coffman K, Azimi M, Rhim JS, Bostwick DG, Snyder P et al. (1999). Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 41: 275-280.
37. Walker-Daniels J, Hess AR, Hendrix MJ, Kinch MS. (2003). Differential regulation of EphA2 in normal and malignant cells. Am J Pathol 162: 1037-1042. (Pubitemid 36350648)
38. Wellbrock C, Ogilvie L, Hedley D, Karasarides M, Martin J, Niculescu-Duvaz D et al. (2004). V599EB-RAF is an oncogene in melanocytes. Cancer Res 64: 2338-2342.
39. Yang G, Zhang G, Pittelkow MR, Ramoni M, Tsao H. (2006). Expression profiling of UVB response in melanocytes identifies a set of p53-target genes. J Invest Dermatol 126: 2490-2506. (Pubitemid 44582271)
40. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. (2001). EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 61: 2301-2306. (Pubitemid 32692063)
41. Zhang G, Njauw CN, Park JM, Naruse C, Asano M, Tsao H. (2008). EphA2 is an essential mediator of UV radiation-induced apoptosis. Cancer Res 68: 1691-1696. (Pubitemid 351416553)